Latest News for: prame

Edit

Landmark Study Shows Combination of Castle Biosciences' DecisionDx�-UM and PRAME Outperforms Gene Mutation Analysis in ...

Nasdaq Globe Newswire 17 Dec 2025
New data show DecisionDx-UM combined with PRAME provides superior prediction of metastasis and survival in uveal melanoma compared to NGS ... .
Edit

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma (Castle Biosciences Inc)

Public Technologies 17 Dec 2025
"The recently published COOG2 study validated that combining DecisionDx-UM test results and PRAME gene expression data provides more precise metastatic risk prediction for patients with UM than either test used independently," said J.
Edit

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial ...

Nasdaq Globe Newswire 11 Dec 2025
... data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors.
Edit

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress (Form 6-K) (Immatics NV)

Public Technologies 11 Dec 2025
Within Immatics' PRAME franchise, its lead PRAME cell therapy, anzu-cel, showed a cORR of 19% during dose escalation (last reported cORR for anzu-cel in Phase 1b at RP2D in melanoma was 56%; anzu-cel is currently in Phase 3 development).
Edit

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps (Form 6-K) (Immatics NV)

Public Technologies 12 Nov 2025
IMA402 PRAME Bispecific Phase 1a Dose Escalation Data Summary ... About PRAME ... anzu-cel (IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy (GEN2), IMA402 PRAME bispecific, anzu-cel in combination with Moderna's PRAME cell therapy enhancer.
Edit

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading ...

Nasdaq Globe Newswire 07 Nov 2025
-- Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing ... .
Edit

T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy ...

Nasdaq Globe Newswire 30 Oct 2025
-- PRAME is a validated target and is expressed in cancers of the skin, uterus, ...
Edit

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at ...

Nasdaq Globe Newswire 20 Oct 2025
... metastatic uveal melanoma treated with anzu-cel PRAME cell therapy.
Edit

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium (Immatics NV)

Public Technologies 20 Oct 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 127163114) .
Edit

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium (Form 6-K) (Immatics NV)

Public Technologies 20 Oct 2025
of Anzu-cel PRAME Cell Therapy ... About PRAME ... anzu-cel (IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy (GEN2), IMA402 PRAME bispecific, anzu-cel in combination with Moderna's PRAME cell therapy enhancer.
  • 1

Article Search

tools
×
×
×
×